Aleta Biotherapeutics
Immuno-oncology platform focused on cell therapy
Aleta’s proprietary CAR-T Engager technology incorporates potent multi-antigen targeting with optimal CAR-T cell fitness and persistence to attack aggressively cancers.
Aleta’s Engager technology can potentially address clinical issues ranging from cell therapy relapse due to antigen loss to overcoming solid tumour heterogeneity. Aleta’s lead program will enter Phase I/II trials in 2023 in collaboration with Cancer Research UK.
CEO Satish Jindal
Advent Contact Raj Parekh
Advent founded Aleta in 2015.
Private Companies
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial
Press Release. Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies …
Read More
Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001
Press Release. Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001 Aleta’s lead program, ALETA-001 has clinical support from collaborator Cancer Research UK, which…
Read More
Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001
Press Release. Designation Intends to Accelerate Regulatory Review Process and Facilitate U.K. Patient Access to Medicines for Seriously Debilitating and Life-Threatening Diseases ALETA-001 Was Developed to Address the Urgent…
Read More
Aleta Biotherapeutics and Cancer Research UK collaborate to advance blood cancer therapy into the clinic
Press Release. NATICK, Mass., June 23, 2021 – Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T…
Read More
